Advances in Screening for Radiation-Associated Cardiotoxicity in Cancer Patients.
Walter SchifferLauren N PedersenMatthew LuiCarmen BergomJoshua D MitchellPublished in: Current cardiology reports (2023)
Cardiac echocardiography, magnetic resonance imaging (MRI), computed tomography, and measurements of troponin and natriuretic peptides serve as the initial screening tests of choice for RICD. Novel imaging applications, including positron emission tomography and specific MRI parameters, and biomarker testing, including myeloperoxidase, growth differentiation factor 15, galectin 3, micro-RNA, and metabolomics, hold promise for earlier detection and more specific characterization of RICD. Advances in imaging and novel applications of biomarkers have potential to identify subclinical RICD and may reveal opportunities for early intervention. Further research is needed to elucidate optimal imaging screening modalities, biomarkers, and surveillance strategies.
Keyphrases
- computed tomography
- positron emission tomography
- magnetic resonance imaging
- contrast enhanced
- high resolution
- randomized controlled trial
- left ventricular
- public health
- pet imaging
- diffusion weighted imaging
- heart failure
- gene expression
- dual energy
- risk assessment
- pulmonary hypertension
- climate change
- dna methylation
- loop mediated isothermal amplification